Skip to main content
. 2020 Feb 27;9(3):558. doi: 10.3390/cells9030558

Figure 6.

Figure 6

Src inhibitors attenuate Smad3 phosphorylation in liver tissues of TAA-injected mice and TGF-β-treated cells. (A) Representative images of IHC staining for phospho-Smad2/3 in the livers of TAA-injected mice treated with or without saracatinib. Original magnification, ×100. All data were normalized against the corresponding values in control animals. Data in the bar graph are expressed as fold increases relative to the control. Data are means ± SEM of five random fields for each liver. ** p < 0.01 compared with the chow group, ## p < 0.01 compared with the TAA-injected chow group. (B–D) Western blot analysis of the effect of saracatinib and PP2 on TGF-β-induced phospho-Smad3 expression in AML12 cells, primary hepatocytes, and LX2 cells. Data in the graph are represented as the mean ± SEM of three independent measurements. * p < 0.01, ** p < 0.01 compared with the control, # p < 0.05, ## p < 0.05 compared with TGF-β.